← Leaderboards
Douglas E Raines
Massachusetts General Hospital
$6,435,191
Attributed
$6,435,191
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $794.4K · FY2010–20$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$6,435,191 · 5
By mechanism
R01$5,828,770 · 3
R21$475,495 · 1
R29$130,926 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Keith W Miller$21,650,712
- Stuart A Forman$18,759,710
- Jonathan B Cohen$9,322,928
- Joseph Avruch$32,720,549
- Emery Neal Brown$29,784,538
Others in their field
Top investigators on “Anesthetics”
- Christian R Abee · University Of South Alabama$18,418,251
- Zhongcong Xie · Massachusetts General Hospital$15,938,941
- Emery Neal Brown · Massachusetts General Hospital$15,430,244
- Frank J Martin · Imedd, Inc.$14,997,320
- Keith W Miller · Massachusetts General Hospital$14,136,125
- Stuart A Forman · Massachusetts General Hospital$13,601,213
Research focus
AnestheticsAnalogGeneral Anesthetic DrugsIn VivoDesignEtomidateAnesthesia ProceduresBinding SitesBaseGeneral AnesthesiaAdverse EffectsMolecularRecoveryVentilatory DepressionNovel StrategiesCritical IllnessOperative Surgical ProceduresPropofolMental DepressionIn VitroPharmaceutical PreparationsAffinityCardiovascular SystemImidazole
Grant awards (18)
Competitive Antagonists for General Anesthetics: A New Class of Drugs for Improving Patient Care and Advancing Scientific Research$390,112
R01 · FY2020 · GM · contact PI
Competitive Antagonists for General Anesthetics: A New Class of Drugs for Improving Patient Care and Advancing Scientific Research$390,112
R01 · FY2019 · GM · contact PI
Competitive Antagonists for General Anesthetics: A New Class of Drugs for Improving Patient Care and Advancing Scientific Research$390,112
R01 · FY2018 · GM · contact PI
Competitive Antagonists for General Anesthetics: A New Class of Drugs for Improving Patient Care and Advancing Scientific Research$407,862
R01 · FY2017 · GM · contact PI
Etomidate Analogues as Safer General Anesthetics$379,651
R01 · FY2016 · GM · contact PI
Etomidate Analogues as Safer General Anesthetics$379,651
R01 · FY2015 · GM · contact PI
Etomidate Analogues as Safer General Anesthetics$379,651
R01 · FY2014 · GM · contact PI
Etomidate Analogues as Safer General Anesthetics$505,714
R01 · FY2013 · GM · contact PI
Etomidate Analogues as Safer General Anesthetics$534,778
R01 · FY2012 · GM · contact PI
Etomidate Analogues as Safer General Anesthetics$534,777
R01 · FY2011 · GM · contact PI
Preclinical Studies of Carbo-etomidate: An Etomidate Analogue for Use in Sepsis$212,305
R21 · FY2011 · DA · contact PI
Etomidate Analogues as Safer General Anesthetics$531,218
R01 · FY2010 · GM · contact PI
Preclinical Studies of Carbo-etomidate: An Etomidate Analogue for Use in Sepsis$263,190
R21 · FY2010 · DA · contact PI
General Anesthetics and nAcCHOR Agonist Affinity$251,283
R01 · FY2004 · GM
General Anesthetics and nAcCHOR Agonist Affinity$251,283
R01 · FY2003 · GM
General Anesthetics and nAcCHOR Agonist Affinity$251,283
R01 · FY2002 · GM
General Anesthetics and nAcCHOR Agonist Affinity$251,283
R01 · FY2001 · GM
GENERAL ANESTHETICS AND LIPID PROTEIN INTERACTIONS$130,926
R29 · FY2000 · GM